Mersana Therapeutics

Ovarian Cancer: Upifitamab Rilsodotin Misses Primary End Point

Source – Mersana Therapeutics According to Mersana Therapeutics, the antibody-drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) did not achieve its ...